Compare TCX & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCX | KPTI |
|---|---|---|
| Founded | 1992 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.9M | 197.3M |
| IPO Year | 2005 | 2013 |
| Metric | TCX | KPTI |
|---|---|---|
| Price | $15.96 | $8.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 20.0K | ★ 507.4K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $362,275,000.00 | $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.76 | 0.57 |
| 52 Week Low | $15.18 | $3.65 |
| 52 Week High | $25.17 | $10.99 |
| Indicator | TCX | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 42.25 | 53.92 |
| Support Level | $15.43 | $5.84 |
| Resistance Level | $18.63 | $9.00 |
| Average True Range (ATR) | 0.75 | 0.59 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 26.53 | 32.40 |
Tucows Inc is a corporate parent, allocating capital and providing efficient shared services to its three businesses. The Company offers Mobile Service Enabler (MSE) solutions, as well as professional services to other retail mobile providers. The Company is also a distributor of Internet services, including domain name registration, digital certificates, and email. It provides these services through an Internet-based distribution network of Internet Service Providers, web hosting companies, and other providers of Internet services to end-users. It operates in three segments: Ting, Wavelo, and Tucows Domains. It generates the majority of its revenue from Tucows Domains. The company generates key revenue from Canada and USA.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).